Compare iShares Bitcoin Trust (IBIT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Natera Inc. Common Stock — how do they compare? iShares Bitcoin Trust trades at $45.8 (market cap $66.43B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: iShares Bitcoin Trust is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 42 Days and Natera Inc. Common Stock for 0 Days on average.
| IBIT | NTRA | |
|---|---|---|
Market Cap | $66.43B | $57.03B |
Volume | 28,050,093 | 1,131,157 |
Sector | Crypto-linked | Health |
52-Week High | $65.28 | $425.64 |
52-Week Low | $33.29 | $179.42 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.13, up 0.58% with neutral technical signals overall. The stock shows bullish moving average momentum but mixed oscillators, with key support at $46 and resistance at $48. Recent institutional inflows and positive ETF performance highlight growing investor interest in BlackRock's Bitcoin trust vehicle, though financial ratios remain undisclosed in current filings.
Outlook remains cautiously optimistic given strong institutional inflows and market positioning. Key risks include regulatory uncertainty and Bitcoin price volatility affecting the trust's underlying value. Analyst sentiment appears balanced with technical indicators suggesting near-term consolidation around current levels.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
